About Reliable Biopharmaceutical Corporation

More News

WHAT'S NEW AT Reliable Biopharmaceutical Corporation

Reliable Biopharmaceutical Corporation Receives Lilly Global Supplier of the Year Award

Reliable Biopharmaceutical Corporation was recently awarded the highly coveted Lilly Global Supplier of the year. This award recognizes those companies who continually help create and sustain Lilly’s competitive edge. In the second year of nomination, Reliable Biopharmaceutical earned this honor received by only .02 percent of all Lilly suppliers. Reliable’s dedication to on time deliveries and quality product manufacturing has earned them this distinguished honor.

Founded in 1968, Reliable Biopharmaceutical Corporation has evolved from a chemical manufacturing plant to a leader in the purified processing chemicals and Active Pharmaceutical Ingredient (API) manufacturer holding eleven active Drug Master Files (DMFs) with more in development. Initial successes with Small Business Innovation Research grants from the National Institutes of Health, including the prestigious Tibbetts Award in 1997, laid the technical foundation that defines Reliable Biopharmaceutical Corporation as a company.

Reliable Biopharmaceutical Corporation manufactures Active Product Ingredients (API’s) for many FDA regulated industries including the parental pharmaceutical, generic pharmaceutical, and cosmetic industries. Also manufactured are intermediate products and highly purified processing chemicals such as enzymes, buffers, and excipients that are used in the finished drug process or the finished drug form. Among these purified processing chemicals are Urea Ultra Pure, Sodium Dedicyl Sulfate- High Purity, Purified Phenol Liquefied, Carboxypeptidase B, and Lactobionic Acid.

The fully audited and cGMP facility is located in St Louis, Missouri and has had many years of strong growth by continuing to be a leader in innovation and purification with customers around the world. Reliable recently commissioned a new high containment suite for the manufacture of potent compounds and significantly increased their headcount to support their future direction.